Cargando...
Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions
This section provides a brief overview of new cancer drugs approved by the FDA between July 24, 2020, and September 4, 2020.
Guardado en:
| Publicado en: | Am Health Drug Benefits |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Engage Healthcare Communications, LLC
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7741173/ https://ncbi.nlm.nih.gov/pubmed/33343822 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|